Business Context and Reporting Period
Company: American Shared Hospital Services
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: The Company provides Gamma Knife radiosurgery units to medical centers through its majority-owned subsidiary, GK Financing, LLC. As of September 30, 2002, the Company operated 14 Gamma Knife units across 12 states. Revenue models include fee-per-use contracts (12 customers) and revenue-sharing "retail" agreements (2 customers).
Key Financial Metrics
| Metric (Nine Months Ended Sept 30) | 2002 | 2001 |
|---|---|---|
| Revenues | $10,024,000 | $8,729,000 |
| Net Income | $914,000 | $859,000 |
| Earnings Per Share (Basic) | $0.25 | $0.24 |
| Net Cash from Operating Activities | $3,016,000 | $3,111,000 |
| Cash and Cash Equivalents (Sept 30) | $10,457,000 | $11,580,000 (Dec 31, 2001) |
| Total Debt (Current + Long-term) | $27,047,000 | $25,920,000 (Dec 31, 2001) |
| Working Capital | $8,090,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 15% ($1,295,000) for the nine months ended September 30, 2002, compared to the prior year. This was driven by the addition of two new Gamma Knife units in 2002, the full nine-month inclusion of two units started in 2001, and a 3% increase in revenue at mature centers.
- Procedure Volume: The number of Gamma Knife procedures increased 17% to 1,274 for the nine-month period, attributed to new unit installations and a 6% increase in procedures at existing units.
- Expense Increases: Total costs of operations rose $730,000 due to increased maintenance (warranty expirations), depreciation (new units), and marketing/insurance costs. Selling and administrative costs increased $181,000, primarily due to payroll and rent, partially offset by reduced costs from subsidiaries OR21 and MedLeader.
- Interest Expense: Interest expense decreased $50,000 for the nine-month period due to lower balances on mature loans, offsetting interest on new unit financing.
- Income Tax: The Company recorded a 40% income tax provision, partially offset by a $168,000 tax benefit from stock option exercises.
Outlook, Risks, and Management Commentary
- Liquidity: Cash and cash equivalents decreased by $1,123,000 during the period, primarily due to property and equipment purchases ($627,000), dividend payments ($438,000), and debt principal payments ($3,228,000).
- Debt Obligations: The Company has scheduled interest and principal payments of approximately $7,787,000 over the next 12 months. Management believes cash flow from operations and existing resources are adequate to meet these obligations.
- Strategic Shifts: The Company has delayed further activity in its MedLeader subsidiary, resulting in cost reductions.
- Controls: Management concluded that disclosure controls and procedures were adequate as of the evaluation date, with no significant changes in internal controls.
- Risks: The filing does not explicitly detail new material risks beyond standard operational and financial obligations. No legal proceedings or defaults on senior securities were reported.
Investor Verification Checklist
- Verify the utilization rates and revenue trends of the two new Gamma Knife units installed in 2002.
- Confirm the status of the "retail" revenue-sharing agreements and the associated operating expense responsibilities.
- Monitor the $7.8 million in scheduled debt payments due within the next 12 months against projected operating cash flows.
- Assess the impact of the delayed MedLeader activity on future diversification and revenue streams.
- Review the warranty expiration schedule for the 11 units currently under contract maintenance to forecast future maintenance cost increases.